Bisantrene in advanced, hormone-resistant carcinoma of the prostate: An Illinois Cancer Council phase II study

Van Hoff DD, Myers JN, Kuhn J, Sandbach JF, Pocelinko R, Clark G, Coltman Jr CA: Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (CL 216,942). Cancer Res 41: 3118–3121, 1981Google Scholar

Murphy GR, Slack NH: Response criteria for the USA National Prostatic Cancer project. Prostate 1: 375–382, 1980Google Scholar

Powis G, Kovach JS: Deposition of bisantrene in humans and rabbits: evidence for intra-vascular deposition of drug as a cause of phlebitis. Cancer Res 43: 1402–1404, 1983Google Scholar

Marschke RF, Kvols LK, Cullinan SA, Laurie JA, Mailliard JA, Tschetter LK, O'Connell MJ: Phase II study of bisantrene administered by continuous 72-hour infusion for advanced pancreatic adenocarcinoma. Med Ped One 16: 269–270, 1988Google Scholar

Raghavan D, Bishop J, Woods R, Page J, Devine R: Mitozantrone (ZAN): A non-toxic moderately active agent for hormone-resistant prostate cancer. (Abstr) Proc Am Soc Clin Oncol 5: 102, #395, 1986Google Scholar

Drelichman A, Osborne CK, Von Hoff D: A phase II clinical investigation of dihydroxyanthracenedione (DHAD) in patients with advanced prostate cancer. (Abstr) Proc Am Soc Clin Oncol 1: 120, #465, 1982Google Scholar

Luz Hammershaimb, M.D., Lederle Laboratories: Personal communication, May 2, 1989Google Scholar